Advances in Therapy

, 28:1 | Cite as

Management of the adverse effects of lenalidomide in multiple myeloma

Review

Abstract

The introduction of new agents in the treatment of multiple myeloma, such as thalidomide, bortezomib, or lenalidomide, has represented an important step forward in the management of this disease, with improvement in both treatment response and patient survival. On the other hand, when new drugs are used it is very important to know their associated toxicity, since adequate management of the adverse effects can help to avoid unnecessary treatment interruptions — thereby undoubtedly contributing to improvement in the efficacy of therapy. The present study reviews the main hematological and nonhematological adverse effects potentially associated with the use of lenalidomide in its most common combinations used for the treatment of multiple myeloma, and the recommendations for dealing with such effects.

Keywords

adverse effects lenalidomide multiple myeloma 

References

  1. 1.
    Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.PubMedCrossRefGoogle Scholar
  2. 2.
    Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006;42:1671–1683.PubMedCrossRefGoogle Scholar
  3. 3.
    Gay F, Palumbo A. Multiple myeloma: management of adverse events. Med Oncol. 2010;27:646–653.PubMedCrossRefGoogle Scholar
  4. 4.
    Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.PubMedCrossRefGoogle Scholar
  5. 5.
    Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.PubMedCrossRefGoogle Scholar
  6. 6.
    Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146:164–170.PubMedCrossRefGoogle Scholar
  7. 7.
    Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82:426–432.PubMedCrossRefGoogle Scholar
  8. 8.
    Ishak J, Dimopoulus MA, Weber D, Knight RD, Shearer A, Caro J. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood (ASH Annual Meeting abstracts). 2008;112:3708.Google Scholar
  9. 9.
    Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME. Eastern Cooperative Oncology Group. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an openlabel randomised controlled trial. Lancet Oncol. 2010;11:29–37.PubMedCrossRefGoogle Scholar
  10. 10.
    Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17:1766–1771.PubMedCrossRefGoogle Scholar
  11. 11.
    Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113:4137–4143.PubMedCrossRefGoogle Scholar
  12. 12.
    Palumbo A, Falco P, Corradini P, et al. GIMEMA-Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459–4465PubMedCrossRefGoogle Scholar
  13. 13.
    Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111:1101–1109.PubMedCrossRefGoogle Scholar
  14. 14.
    Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050–4503.PubMedCrossRefGoogle Scholar
  15. 15.
    Chanan-Khan AA, Yu Z, Weber D, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood (ASH Annual Meeting abstracts). 2006;108:3554.Google Scholar
  16. 16.
    Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function: Cancer. 2010;116:3807–3814.PubMedCrossRefGoogle Scholar
  17. 17.
    Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia/rompocytopenia and time to event results. Haematologica. 2008;93(suppl. 1):96Google Scholar
  18. 18.
    Reece D, Masih-Khan, Chen C, et al. Lenalidomide (Revlimid)±costicosteroid in elderly patients with relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting abstracts). 2006;108:3550.Google Scholar
  19. 19.
    Blade J. Complications of multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1231–1246.PubMedCrossRefGoogle Scholar
  20. 20.
    Palumbo A, Rajkumar SV, Dimopoulus MA, et al. International Myeloma Working Group. Prevention of thalidomide and lenalidomide associated trombosis in myeloma. Leukemia. 2008;22:414–423.PubMedCrossRefGoogle Scholar
  21. 21.
    Weber D, Rankin K, Gavion M, Dalasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16–19.PubMedCrossRefGoogle Scholar
  22. 22.
    Neben K, Moehler T, Benner A, et al. Dosedependent effect of thalidomide on overall survivel in relapsed multiple myeloma. Clin Cancer Res. 2002;8:3377–3382.PubMedGoogle Scholar
  23. 23.
    Zangari M, Anaissie E, Barlogi B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–1615.PubMedCrossRefGoogle Scholar
  24. 24.
    Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991–4998.PubMedCrossRefGoogle Scholar
  25. 25.
    Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006;134:399–405.PubMedCrossRefGoogle Scholar
  26. 26.
    Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide associated venous thromboembolism. Blood Coagul Fibrinol. 2009;20:3377–3339.CrossRefGoogle Scholar
  27. 27.
    Brandenburg NA, Goss TF, Knight T, Xu X, Knight RD. Evaluation of the relationship between venous thromboembolism risk factors and the use of antithrombotic prophylaxis in multiple myeloma patients treated with thalidomide and dexamethasone combination regimens. Blood (ASH Annual Meeting abstracts). 2008;112:2369.Google Scholar
  28. 28.
    Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010;116:22–26.PubMedCrossRefGoogle Scholar
  29. 29.
    Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009;114:772–778.PubMedCrossRefGoogle Scholar
  30. 30.
    Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–3067.PubMedCrossRefGoogle Scholar
  31. 31.
    Zangari M, Tricot G, Zeldis J, Eddelmon P, Saghafifar F, Barlogi B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapsed after high dose of chemotherapy. Blood (ASH Annual Meeting abstract). 2001:98:3225.Google Scholar
  32. 32.
    Zonder JA, Barlogie B, Durie DG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood (ASH Annual Meeting abstracts). 2006;108:403.Google Scholar
  33. 33.
    Knight T, DeLap RJ, Zeldis JB. Lenalidomide and venous trombosis in multiple myeloma. N Engl J Med. 2006;354:2079–2080.PubMedCrossRefGoogle Scholar
  34. 34.
    Zangari M, Tricot G, Poavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high dose dexamethasone. J Clin Oncol. 2009;28:132–135.PubMedCrossRefGoogle Scholar
  35. 35.
    Wright JA, Weber D, Thomas SK, et al. Characteristics of patients experiencing thomboembolic events during treatment for multiple myeloma: asprin may not be adecuate thromboprofilaxis in patients with multiple risk factors. Blood (ASH Annual Meeting abstracts). 2007;110:1882.Google Scholar
  36. 36.
    Klein U, Kosely F, Hillegab J, et al. Effective prophylaxis with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol. 2009;88:67–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Palumbo A, Dimopoulus M, San Miguel J, Harousseau JL, Attal M, Hussein M. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Reviews. 2009;23:87–93.PubMedCrossRefGoogle Scholar
  38. 38.
    Weber DM, Spencer A, Wang M, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma with impaired renal function. J Clin Oncol (Annual Meeting of American Society of Clinical Oncology abstracts). 2008;26:8542.Google Scholar
  39. 39.
    Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J. Lenalidomideinduced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007;138:640–643.PubMedCrossRefGoogle Scholar
  40. 40.
    Simpson I, Rajkumar SV. Dispenzieri A. High incidente of diarrhea in patients on long term teraphy with lenalidomide and dexamethasone for multiple myeloma. J Clin Oncol. 2008;26:8586.Google Scholar
  41. 41.
    Kumar S, Giralt S, Stadmauer EA. Mobilization in myeloma revisited: IMWG consensus perspectiveson stem cell collection following inicial therapy with thalidomide-, lenalidomideor bortezomib containing regimens. Blood. 2009:114;1729–1735.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2011

Authors and Affiliations

  1. 1.Hematology DepartmentHospital Central de AsturiasOviedo, AsturiasSpain

Personalised recommendations